IP Library Granted Patent US 12,201,700
Granted Patent B2
US 12,201,700 · App. 15/766,039 · Granted Jan 21, 2025

Micro- and nano-device for cartilage injury detection and treatment

Inventors: Liping Tang (Arlington, TX); Jun Zhou (Arlington, TX); Joseph Borrelli (Dallas, TX)
Assignees: Joseph Borreli; Board of Regents, The University of Texas System
A61K49/0054A61K9/0019A61K38/1841A61K38/195A61K47/551A61K47/61A61K47/6939A61K49/0032A61K49/0052A61K49/0091A61K49/0093C08B37/0072G01N33/6872G01N33/82G01N2333/70585G01N2800/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,700
App. No.
15/766,039
Granted
Jan 21, 2025
Kind
B2
Abstract

The present invention provides targeting probe, imaging probes, and probes for use as a medicament to treat damaged cartilage, where the probe targets injured tissue and can then be imaged and/or release agents to trigger the migration of surrounding chondrocytes from healthy tissue to injured tissue and/or recruit synovial stem cells.

Claims (42)

1. An arthritic cartilage targeting probe comprising:

a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization;

a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and

a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration.

2. A damaged cartilage targeting probe comprising:

a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization;

a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; and

a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration.

3. A method for identifying damaged cartilage comprising:

providing a damaged cartilage targeting probe that comprises a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4; wherein the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof;

contacting a cartilage suspected of being damaged with the damaged cartilage targeting probe; and

detecting the damaged cartilage targeting probe.

4. A cartilage targeting probe to treat damaged cartilage by recruiting stem cells, chondrocytes or both to the damaged cartilage, wherein the cartilage targeting probe comprises:

a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization;

a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets;

one or more chemokines selected from SDF 1, SDF 1β, Epo, CCL2, CCL16, VEGF, TGF-β1 and TGF-β3, associated with the polymer targeting probe, wherein the one or more chemokines are released to recruit stem cells, chondrocytes or both; and

a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof.

5. A cartilage targeting probe to treat damaged cartilage by increasing chondrogenic differentiation, wherein the cartilage targeting probe comprises:

a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization;

a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets;

one or more TGF active agents selected from TGF-β1 and TGF-β3 associated with the polymer targeting probe, wherein the one or more TGF active agents are released to trigger higher chondrogenic differentiation; and

a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration.

6. The arthritic cartilage targeting probe of claim 1 , wherein the ligand is hyaluronic acid and the one or more cell surface targets is a CD44 receptor.

7. The arthritic cartilage targeting probe of claim 1 , wherein the ligand is a folic acid and the one or more cell surface targets is a folate receptor.

8. The arthritic cartilage targeting probe of claim 1 , wherein the damaged cartilage is from mechanical trauma, physical trauma compression trauma, arthritic damage, inflammatory damage or a combination thereof.

9. The arthritic cartilage targeting probe of claim 1 wherein the molecular weight is about 10K, 60K, 700k, 1.5M or incremental variations thereof.

10. The arthritic cartilage targeting probe of claim 1 , wherein the crosslinking ratio is 1:4, 1:3, 1:2, 1:1, 1:3.9, 1:3.5, 1:2.3, 4:1, 3:1, 2:1 and incremental variations thereof.

11. The arthritic cartilage targeting probe of claim 1 , wherein the detectable tag is a fluorescent dye, a radioactive tag, a metal, a nanoparticle or a combination thereof.

12. The arthritic cartilage targeting probe of claim 1 , wherein the polymer targeting probe is biodegradable.

13. The arthritic cartilage targeting probe of claim 4 , wherein the one or more chemokines or one or more TGF active agents are bound to the crosslinked biopolymer, releasably associated, disposed in the crosslinked biopolymer, spray coated on the crosslinked biopolymer or a combination thereof.

14. The arthritic cartilage targeting probe of claim 4 wherein the crosslinked biopolymer comprises one or more pores and the one or more chemokines or one or more TGF active agents are disposed in the one or more pores for extended release over time.

15. The arthritic cartilage targeting probe of claim 14 , wherein the one or more pores have a diameter of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 nm or less than 1 nm or greater than 29 nm.

16. The arthritic cartilage targeting probe of claim 1 , wherein the polymer targeting probe contacts the one or more targets in less than 15 minutes to allow the quick detection within 15 minutes.

17. The arthritic cartilage targeting probe of claim 1 , the polymer targeting probe is intra-articular injected.

18. The arthritic cartilage targeting probe of claim 1 , wherein the targeting probe is used to image the damaged/injured cartilage and deliver one or more active agents to the damaged/injured cartilage.

19. A damaged/injured cartilage imaging probe for use as a medicament to target and/or treat damaged cartilage, wherein the damaged cartilage imaging probe comprises

a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization;

a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and

a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the detectable tag can be detected at the damaged cartilage and used to generate an image of the damaged cartilage, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration.

20. A damaged cartilage probe for use as a medicament for targeted treatment of damaged cartilage, wherein the damaged cartilage probe comprises:

a cartilage damaged imaging probe for identifying damaged cartilage, wherein the cartilage damaged imaging probe comprises a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the detectable tag can be detected at the damaged cartilage and used to generate an image of the damaged cartilage; and

a cartilage targeting probe for use as a medicament to treat damaged cartilage by recruiting stem cells, chondrocytes or both to the damaged cartilage, wherein the cartilage targeting probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has the diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more chemokines selected from SDF 1, SDF 1β, Epo, CCL2, CCL16, VEGF, TGF-β1 and TGF-β3, associated with the polymer targeting probe, wherein the one or more chemokines are released to recruit stem cells, chondrocytes or both; and optionally a second detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof; and optionally a chondrogenic differentiation probe for use as a medicament to treat damaged cartilage by increasing chondrogenic differentiation, wherein the chondrogenic differentiation probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of greater than about 200 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more TGF active agents selected from TGF-β1 and TGF-β3 associated with the polymer targeting probe, wherein the one or more TGF active agents are released to trigger higher chondrogenic differentiation; and a third detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 7, 2023
From: UNIVERSITY OF TEXAS ARLINGTON
To: UNITED STATES GOVERNMENT
Reel/Frame 062967/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: TANG, LIPING; ZHOU, JUN
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 045619/0008 →
Continuity (2)
Provisional Application 62237217 · Oct 5, 2015
Related Publication 20180296706A1 · Oct 18, 2018
References Cited (58)
US 9017644B2 · Baker, Jr. et al. · 2015 [cited by applicant]
US 20080031850A1 · Bader · 2008 [cited by applicant]
US 20110256628A1 · Galperin et al. · 2011 [cited by applicant]
US 20120128741A1 · Gravett et al. · 2012 [cited by applicant]
CN 103690971A · 2014 [cited by applicant]
JP 2001231401 · 2001 [cited by applicant]
JP 2007517001 · 2007 [cited by applicant]
JP 2009544690 · 2009 [cited by applicant]
JP 2011506734 · 2011 [cited by applicant]
WO 2007098770 · 2007 [cited by applicant]
WO 2009077620A1 · 2009 [cited by applicant]
WO WO2009077399A1 · 2009 [cited by examiner]
WO 2012145439 · 2012 [cited by applicant]
WO 2013027854A1 · 2015 [cited by applicant]
WO 2017062493 · 2017 [cited by applicant]
WO 2017062493A1 · 2017 [cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for PCT/US2016/055552 dated Jan. 9, 2017, 14 pp. [cited by applicant]
Ibrahim, et al., “The Impact of HA Oligomer Content on Physical, Mechanical, and Biologic Properties of Divinyl Sulfone-Crosslinked HA Hydrogels,” J. Biomed. Mater. Res. A., vol. 94(2), Aug. 2010, pp. 355-370. [cited by applicant]
Shimojo, et al., “The Performance of Crosslinking with Divinyl Sulfone as Controlled by the Interplay Between the Chemical Modification and Conformation of Hyaluronic Acid,” J. Braz. Chem. Soc., vol. 26, No. 3, 2015, pp… [cited by applicant]
Baker, David W., et al., “Development of optical probes for in vivo imaging of polarized macrophages during foreign body reactions,” Acta Biomaterialia, vol. 10, Apr. 13, 2014, pp. 2945-2955. [cited by applicant]
Chen, Wei-Tsung, et al., “Arthritis imaging using a near-infrared fluorescence folate-targeted probe,” Arthritis Res. & Ther., vol. 7 No. 2 Jan. 14, 2005, pp. R310-R317. [cited by applicant]
Fani, M., et al., “In Vivo Imaging of Folate Receptor Positive Tumor Xenografts Using Novel Ga-NODAGA-Folate Conjugates,” Molecurlar Pharmaceutics, vol. 9, Apr. 12, 2012, pp. 1136-1145. [cited by applicant]
Huang, Peng, et al., “Folic acid-conjugated Silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy,” Biomaterials, vol. 32, Sep. 13, 2011, pp. 9796-9809. [cited by applicant]
Li, J., et al., “Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR maging,” Biomaterials, 34, Aug. 7, 2013, pp. 8382-8392. [cited by applicant]
Zhou, Jun, et al., “In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging proble,” Bioorganic & Medicinal Chemistry Letters, vol. 23, Feb. 13… [cited by applicant]
Zhou, Jun, et al., “Real time monitoring of biomaterial-mediated inflammatory responses via macrophage-targeting NIR nanoprobes,” Biomaterials, vol. 32, Sep. 3, 2011, pp. 9383-9390. [cited by applicant]
Zhou, Min, et al., “A Chelator-Free Multifunction [64Cu]CuS Nanoparticle Platform for simultaneous Micro-PET/CT Imaging and Photothermal Ablation Therapy,” JACS vol. 132, Oct. 13, 2010, pp. 15351-15358. [cited by applicant]
Zhou, Min, et al., “Theranostic CuS nanoparticles targeting folate receptors for PET image-guided photothermal therapy,” J. Mater. Chem. B., vol. 3, Oct. 19, 2015, pp. 8939-8948. [cited by applicant]
Borzachhiello, A., et al., “Hyaluronic Acid Based Hydrogels for Regenerative Medicine Applications,” BioMed Research International, Mar. 6, 2015, 12 pp. [cited by applicant]
Fakhari, A., et al., “Applications and Emerging Trends of Hyaluronic Acid in Tissue Engineering, as a Dermal Filler, and in Osteoarthritis Treatment,” Acta Biomater, Jul. 2013, vol. 9(7), pp. 7081-7092. [cited by applicant]
Fakhari, A., Dissertation entitled “Biomedical Application of Hyaluronic Acid Nanoparticles,” submitted to Bioengineering of University of Kansas and Defended Jan. 19, 2012, 154 pp. [cited by applicant]
Ibrahim, S., et al., “The Impact of HA Oligomer Content on Physical, Mechanical, and Biologic Properties of Divinyl Sulfone-Crosslinked HA Hydrogels,” J. Biomed. Mater. Res. A., vol. 94(2), Aug. 2010, pp. 355-370. [cited by applicant]
International Search Report and Written Opinion of the United States Patent and Trademark Office for PCT/US2016/055552 dated Jan. 9, 2017, 14 pp. [cited by applicant]
Lai, Jui-Yang, “Relationship between structure and cytocompatibility of divinyl sulfone cross-linked hyaluronic acide,” Carbohydrate Polymers, Sep. 25, 2013, vol. 101, pp. 203-212. [cited by applicant]
Shimojo, A.A.M., et al., “The Performance of Crosslinking with Divinyl Sulfone as Controlled by the Interplay Between the Chemical Modification and Conformation of Hyaluronic Acid,” J. Braz. Chem. Soc., vol. 26, No. 3, … [cited by applicant]
Xu, X., et al., “Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2,” Acta Biomaterialia, Apr. 24, 2011, vol. 7, pp. 3050-3059. [cited by applicant]
Yeom, et al., “Effect of Cross-Linking Reagents for Hyaluronic Acid Hydrogel Dermal Fillers on Tissue Augmentation and Regeneration,” Bioconjugate Chem., Jan. 15, 2010, vol. 21, pp. 240-247. [cited by applicant]
Yoon, H. Y., et al., “Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy,” Biomaterials, vol. 33, Feb. 24, 2012, pp. 3980-3989. [cited by applicant]
Yu, Y., et al., “One-Step ‘Click’ Method for Generating Vinyl Sulfone Groups on Hydroxyl-Containing Water-Soluble Polymers,” BioMacromolecules, Jan. 9, 2012, vol. 13, pp. 937-942. [cited by applicant]
Extended European Search Report of EP16854239.7 issued by the EPO on Sep. 14, 2018. [cited by applicant]
Kato, Y., et al., “Accessibility of high molecular weight hyaluronan to articular cartilage and synovium,” Clinical Rheumatol. Vol. 21, Oct. 20, 2008, pp. 20-31. [cited by applicant]
Rey-Rico, A., et al., “Adapted chondrogenic differentiation of human mesenchymal stem cells via controlled release of TGF-B1 from poly(ethylene oxide)-terephtalate/poly(butylene terepthalate) multiblock scaffolds,” Soci… [cited by applicant]
Turk, M.J., et al., “Folate-Targeted Imaging of Activated Macrophages in Rats with Adjuvant-Induced Arthritis,” Arthritis & Rheumatism, vol. 46, No. 7, Jul. 2002, pp. 1947-1955. [cited by applicant]
Shcharbin, et al. “How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo” Journal of Controlled Release, Available online Mar. 4, 2014, 181 (2014) 40-52. [cited by applicant]
Muller, et al. “Determination of Molecular Weight, Particle Size, and Density of High Number Generation PAMAM Dendrimers Using MALDI-TOF-MS and nES-GEMMA” Macromolecules 2007, 40, 5599-5605, Published on Web Jun. 20, 20… [cited by applicant]
Pradal, et al. “Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice” International Journal of Pharmaceutics 498 (2016) 119-129, Available online Dec. 10… [cited by applicant]
Naor, D., et al., “Review CD44 in rheumatoid arthritis,” Arthritis Res Ther, Feb. 28, 2003, 5:105-115. [cited by applicant]
China National Intellectual Property Administration, Examination Report for China Patent Appl. No. 201680069894.7 dated Oct. 10, 2021, 23 pp. [cited by applicant]
China National Intellectual Property Administration, 2nd Examination Report for China Patent Appl. No. 201680069894.7 dated Jul. 5, 2021, 23 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Jun. 3, 2019, 4 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Aug. 12, 2019, 5 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Nov. 18, 2019, 6 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Apr. 23, 2020, 4 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Jul. 14, 2020, 4 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Sep. 4, 2020, 5 pp. [cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Feb. 17, 2020, 7 pp. [cited by applicant]
Japan Patent Office, Notification of Refusal for Japan Appl. No. 2018-536714, Dated May 27, 2019, 13 pp. [cited by applicant]
Japan Patent Office, Notification of Refusal for Japan Appl. No. 2018-536714, Dated Dec. 9, 2019, 13 pp. [cited by applicant]